Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart mapping technique could make VT ablation safer

NCT ID NCT06464315

Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new mapping method for ventricular tachycardia (VT) ablation that avoids purposely triggering VT. Instead, it uses special software to identify slow-conduction areas during normal heart rhythm. The goal is to see if this approach reduces VT recurrence, death, or complications. The study involves 36 Veterans with scar-related VT undergoing clinically indicated ablation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Functional Substrate-Only Mapping (a procedure using isochronal late activation mapping and peak frequency analysis during voltage mapping)
What this could lead to
If successful, this could make VT ablation safer and more effective by avoiding the risks of intentionally triggering dangerous heart rhythms during the procedure.
What could go wrong
This is a small, early-phase study with only 36 participants, so results may not apply to all patients. The new mapping technique may not be as effective as standard methods in preventing VT recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women \>18 years of age referred for clinically indicated VT ablation and experience monomorphic or polymorphic scar-based VT documented by telemetry, ICD interrogation, ECG or event monitoring. * Scar-based VT is defined as VT in patients with structural heart disease (assessed with either abnormal nuclear perfusion imaging (\>5% defect), late gadolinium uptake on cardiac MRI, wall thinning \<10mm or calcified myocardium on cardiac CT, akinesis or hypokinesis on echocardiogram, presence of Q waves on ECG, history of myocardial infarct). * Patients undergoing epicardial VT ablation and who undergo prophylactic percutaneous hemodynamic support devices will also be included. Exclusion Criteria: * Patients without structural heart disease will be excluded from the pri-mary analysis, but enrolled in a prospective registry * Patients who are pregnant * Presence of intracardiac thrombus * active acute coronary ischemia with unrevascularized coronary artery disease (CAD \>70% stenosis) * Active bacteremia * Inaccessible ventricles due to dual mechanical valves * Inability to tolerate and inability to tolerate anticoagulation during ablation and for at least 1 month after ablation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sudden cardiac death are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Death, Sudden, Cardiac sudden arrhythmia death syndrome sudden cardiac arrest ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sudden cardiac death Ventricular tachycardia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • VA San Diego Healthcare System, San Diego, CA

    San Diego, California, 92161-0002, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.